High-dose rifampicin to treat tuberculosis infection: potential and pitfalls

被引：0
|
作者：
Ryckman, Theresa S. [1 ]
Salazar-Austin, Nicole [2 ]
机构：
[1] Johns Hopkins Sch Med, Div Infect Dis, Baltimore, MD 21230 USA
[2] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD 21230 USA
来源：
LANCET RESPIRATORY MEDICINE | 2024年 / 12卷 / 06期
关键词：
D O I：
10.1016/S2213-2600(24)00107-3
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：420 / 421
页数：2
相关论文
共 50 条
  • [41] Successful Treatment of Persistent MRSA Bacteremia using High-dose Daptomycin Combined with Rifampicin
    Hagiya, Hideharu
    Terasaka, Tomohiro
    Kimura, Kosuke
    Satou, Asuka
    Asano, Kikuko
    Waseda, Koichi
    Hanayama, Yoshihisa
    Otsuka, Fumio
    INTERNAL MEDICINE, 2014, 53 (18) : 2159 - 2163
  • [42] HIGH-DOSE CIPROFLOXACIN IN THE TREATMENT OF A RENAL CYST INFECTION
    ROSSI, SJ
    HEALY, DP
    SAVANI, DV
    DEEPE, G
    ANNALS OF PHARMACOTHERAPY, 1993, 27 (01) : 38 - 39
  • [43] High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
    Boeree, Martin J.
    Heinrich, Norbert
    Aarnoutse, Rob
    Diacon, Andreas H.
    Dawson, Rodney
    Rehal, Sunita
    Kibiki, Gibson S.
    Churchyard, Gavin
    Sanne, Ian
    Ntinginya, Nyanda E.
    Minja, Lilian T.
    Hunt, Robert D.
    Charalambous, Salome
    Hanekom, Madeleine
    Semvua, Hadija H.
    Mpagama, Stellah G.
    Manyama, Christina
    Mtafya, Bariki
    Reither, Klaus
    Wallis, Robert S.
    Venter, Amour
    Narunsky, Kim
    Mekota, Anka
    Henne, Sonja
    Colbers, Angela
    van Balen, Georgette Plemper
    Gillespie, Stephen H.
    Phillips, Patrick P. J.
    Hoelscher, Michael
    LANCET INFECTIOUS DISEASES, 2017, 17 (01): : 39 - 49
  • [44] Comparing efficacy and safety of high-dose and standard-dose rifampicin in the treatment of brucellosis: a randomized clinical trial
    Salehi, Mohammadreza
    Farbod, Farnaz
    Khalili, Hossein
    Rahmani, Hamid
    Jafari, Sirous
    Abbasi, Ali
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (04) : 1084 - 1091
  • [45] Pharmacokinetics and tolerability of high vs. standard dose of rifampicin in pulmonary tuberculosis patients
    Nijland, H.
    Ruslami, R.
    Alisjahbana, B.
    Parwati, I.
    van Crevel, R.
    Aarnoutse, R.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2007, 12 : 74 - 75
  • [46] THE PHARMACOKINETICS OF HIGH-DOSE CYCLOPHOSPHAMIDE AND HIGH-DOSE ETOPOSIDE
    CUNNINGHAM, D
    CUMMINGS, J
    BLACKIE, RB
    MCTAGGART, L
    BANHAM, SW
    KAYE, SB
    SOUKOP, M
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1988, 5 (02): : 117 - 123
  • [47] Limiting the Potential Harms of High-Dose Opioid Therapy
    Sullivan, Mark D.
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (07) : 691 - 693
  • [48] Digital necrosis: a potential risk of high-dose norepinephrine
    Daroca-Perez, Rafael
    Carrascosa, Miguel F.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2017, 8 (08) : 259 - 261
  • [49] Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
    te Brake, Lindsey H. M.
    Boeree, Martin J.
    Aarnoutse, Robert E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199 (09) : 1166 - 1167
  • [50] Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence
    Rockwood, Neesha
    Sirgel, Frederick
    Streicher, Elizabeth
    Warren, Robin
    Meintjes, Graeme
    Wilkinson, Robert J.
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 (06): : 632 - 640
12345